摘要:
The invention relates to compounds of formula (I) as well as to the tautomeric forms thereof, possible enantiomeric and diastereomeric forms and the prodrugs thereof, the production and use thereof, whereby the values have the meaning as given in the description.
摘要:
The present invention relates to novel benzimidazoles, the production thereof and the utilisation as inhibitors of the enzyme poly(ADP-ribose)polymerase or PARP (EC 2.4.2.30) for producing medicaments.
摘要:
The invention relates to a compound of formula (I) or (II), wherein A represents a saturated or mono-unsaturated carbocycle containing 3 to 8 carbon atoms which can also have a condensed benzol ring, whereby the rings can also be substituted with one or two different or identical radicals; R1 represents hydrogen, chlorine, fluorine, bromine, iodine, branched and unbranched C¿1?-C6-alkyl, OH, nitro, CF3, CN, NR?11R12¿, NH-CO-R13, O-C1-C4 alkyl; and R2 represents hydrogen, branched and unbranched C¿1?-C6 alkyl, C1-C4 alkyl-phenyl. The invention also relates to the tautomeric forms, possible enantiomeric and diastereomeric forms, possible cis-trans isomers on the rings in A and their prodrugs. The substituted benzimidazoles of general formulas (I) and (II) are inhibitors of poly(ADP-ribose) polymerase (PARP), or poly(ADP-ribose) synthase (PARS), as it is also known and can be used for the treatment or prophylaxis of diseases which are associated with the increased enzyme activity of this enzyme.
摘要:
The invention relates to novel indole derivatives, to the production thereof and to the use thereof as inhibitors of the enzyme poly(ADP ribose)polymerase or PARP (EC 2.4.2.30) for producing medicaments.
摘要:
The invention relates to compounds of formula (I) as well as to the tautomeric forms thereof, possible enantiomeric and diastereomeric forms and the prodrugs thereof, the production and use thereof, whereby the values have the meaning as given in the description.
摘要:
The invention relates to compounds of formula (I), wherein; either A1 or A2 represents CONH¿2?, and the other radical A?2 or A1¿ represents hydrogen, chlorine, fluorine, bromine, iodine C¿1?-C6 alkyl, OH, nitro, CF3, CN, NR?11R12¿, NH-CO-R13, O-C1-C4 alkyl; X1 can represent N and C-R2; X2, independent of X1, can represent N and C-R2; R2 can represent hydrogen, C¿1?-C6 alkyl, C1-C4 alkyl-phenyl, phenyl; B can represent an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 15 carbon atoms, an unsaturated, saturated or partially unsaturated monocyclic, bicyclic or tricyclic ring having a maximum of 14 carbon atoms and 0 to 5 nitrogen atoms, 0 to 2 oxygen atoms or 0 to 2 sulfur atoms, which can each still be substituted with an R?4¿ and a maximum of 3 of the same or different radicals R5, and; R?1, R4, R5, R11-R13¿ have the meanings as cited in Claim No. 1. The invention also relates to the tautomeric forms, and possible enantiomeric and diastereomeric forms of said compounds, to the prodrugs thereof and to their use as PARP inhibitors.
摘要:
The invention relates to compounds of general formula (1a) or (1b) wherein R?1 and R4¿ are hydrogen or defined substituents, A is a saturated or monoethenoid heterocyclic ring with 4 to 8 members which contains one or two nitrogen atoms, wherein additionally one oxygen or sulfur atom can be present. Said ring can be further substituted. The invention also relates to their tautomer forms, possible enantiomer and diastereomer forms, their prodrugs, as well as possible physiologically acceptable salts. The invention also relates to the use of said compounds for treating diseases related to a pathologically increased activity of PARP.